Navigation Links
Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
Date:3/2/2013

edict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.  These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011.  Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking Statements
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  These statements concern, and these risks and uncertainties include, among others, the nature, timi
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
2. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
3. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
4. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
5. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
8. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
9. Sanofi Pasteur to add 2D barcode to six more vaccines
10. Sanofi US Launches Collaborate Activate Innovation Challenge
11. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ST. PAUL, Minn. , July 7, 2015 /PRNewswire/ ... and manufacturer of devices that use neuroblocking technology to ... the pricing of its previously announced public offering of 32,000,000 ... stock and one Series A warrant to purchase one ... $0.50 per unit. Investors whose purchase of units in ...
(Date:7/7/2015)... -- Oasmia Pharmaceutical AB, a developer of ... oncology, has filed a registration statement on Form F-1/A ... the proposed public offering of ordinary stock and listing ... Depositary Shares, representing ordinary shares, to be offered, and ... been determined. An Investor Roadshow will be conducted in ...
(Date:7/7/2015)... July 7, 2015 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral ... a non-binding Letter of Intent (LoI) for an investment ... with Sinopharm Capital Management Co. Ltd. and Hefei Life ... (Sinopharm/ Hefei ) potentially valued at $50,000,000 ...
Breaking Medicine Technology:EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing and Announces Investor Roadshow 2Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China 2Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China 3Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China 4Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China 5
... , , MADISON, N.J., ... ), the world,s leading provider of diagnostic testing, information and ... 21st Annual Piper Jaffray Healthcare Conference in New York City. ... at 9:30 a.m. Eastern Time. , During the conference, the ...
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today ... Healthcare Conference on Tuesday, December 1, 2009 at 9:00 a.m. ... at The New York Palace Hotel. Steve Worland, Ph.D., ... overview of Anadys and its clinical development programs, ANA598 and ...
Cached Medicine Technology:Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2
(Date:7/7/2015)... ... July 07, 2015 , ... SC&H Group, a leading audit, tax, and ... back to the community through company-wide volunteering efforts. , On an annual basis, in ... to assisting those in need throughout Baltimore and Washington D.C. , This ...
(Date:7/7/2015)... ... July 07, 2015 , ... Summer is a great time to get ... Insurance is sharing some safety tips. , Jean Tapley, senior wellness coordinator at Amica, ... , Start slowly. Going from no activity to several hours ...
(Date:7/7/2015)... ... , ... Parents and guardians of teenagers or young adults will be interested ... center for drug and alcohol abuse located in Southwest Michigan. A recently released study ... significant increase in the “club drug” use among high school seniors. The blog post ...
(Date:7/7/2015)... ... July 07, 2015 , ... With a new community program in the ... Angels and announced a new charity campaign to raise funds in support of programs ... Angels, which was created especially to care for the special needs of our soldiers. ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... environments with the introduction of the Nightstick XPP-5422GM , the world’s first ... one at its base and one on its clip. The new Nightstick XPP-5422GM ...
Breaking Medicine News(10 mins):Health News:SC&H Group Celebrates 9th Annual Day of Service 2Health News:Amica Insurance Has 7 Summer Safety Tips 2Health News:A Forever Recovery Releases New Information on “Club Drugs” and Tips for Parents of Teens and Young Adults 2Health News:Clear Insurance Group and Nonprofit Soldiers’ Angels Initiate New Charity Campaign in San Antonio, TX to Provide Aid and Comfort for Veterans 2Health News:Clear Insurance Group and Nonprofit Soldiers’ Angels Initiate New Charity Campaign in San Antonio, TX to Provide Aid and Comfort for Veterans 3Health News:Dual Magnets Add Convenience to Safety in New Nightstick® XPP-5422GM Intrinsically Safe Dual-LightTM Flashlight 2Health News:Dual Magnets Add Convenience to Safety in New Nightstick® XPP-5422GM Intrinsically Safe Dual-LightTM Flashlight 3
... , ... The Maryland Hospital Association’s (MHA) Quality Indicator ... integrate the QI Project Core Measures solution with 3M™ ClinTrac™ Quality ... and outpatient core measures data, advanced analytical tools, and comparative reports ...
... an important clue in the quest to understand why people who ... keep well in the long term. A study led ... respond normally to emotional stimuli, such as when they see happy, ... in the American Journal of Geriatric Psychiatry and is ...
... MAY 4, 2010 TCT for Surgeons will showcase ... the field that are improving outcomes for patients undergoing ... will run during Transcatheter Cardiovascular Therapeutics (TCT) 2010 (September ... Foundation. "This meeting will drive forward the growing ...
... ... ... Bold Software recently announced the second annual release of a report detailing the industry’s ... combined with the company’s recent benchmarking analysis, shows that not only does proactive chat ...
... of these medications more safe , TUESDAY, May 4 ... antidepressant is more likely to boost the risk that ... try to commit suicide. , In the past, there ... inhibitors such as Prozac and Paxil, raise the risk ...
... , ... published online by over 3,000 dermatologists to inform their patients and the public about the ... ... is the most frequently diagnosed of all cancers and dermatologists are providing their patients with ...
Cached Medicine News:Health News:3M and Maryland Hospital Association's Quality Indicator Project Partner to Deliver Comprehensive Quality Solution 2Health News:3M and Maryland Hospital Association's Quality Indicator Project Partner to Deliver Comprehensive Quality Solution 3Health News:Why is late-life depression harder to treat? 2Health News:Fear of Proactive Chat Unfounded According to Research by Bold Software 2Health News:Fear of Proactive Chat Unfounded According to Research by Bold Software 3Health News:Fear of Proactive Chat Unfounded According to Research by Bold Software 4Health News:Fear of Proactive Chat Unfounded According to Research by Bold Software 5Health News:No One Antidepressant Raises Suicide Risk More Than Others 2Health News:Skin Cancer Education Provided by 3,000 Dermatologists for Skin Cancer Awareness Month 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: